For almost six decades, Pharmathen has remained committed to its vision of improving patients’ lives through innovation and expanding access to complex pharmaceutical therapies.
Today, Pharmathen's capabilities extend across a broad range of specialized dosage forms, including sustained-release products, long-acting injectables, and oral solid dosage forms, while its portfolio includes more than 100 commercial products available internationally through a strong network of partners.
These activities are supported by a robust Research & Development and Manufacturing ecosystem, with three facilities in Greece.
The driving force behind Pharmathen is its people. With more than 1,600 employees representing 27 nationalities, the company fosters a multicultural workplace where women account for 53% of the workforce and 40% of the Senior Leadership Team.
Grounded in its shared values of integrity, quality, innovation, leadership and performance, and guided by strong business ethics and a commitment to its vision, Pharmathen remains dedicated to its founding mission: improving patients' lives.
Pharmathen offers a great opportunity for career development and is seeking to recruit a Raw Materials Analyst to join our team at our Sapes premises.
As a Raw Materials Analyst, you will beresponsible for conducting RAW materials’ quality control testing adhering to standard operating procedures and under GMPs.
More particularly:
Join our team and experience the unique Pharmathen’s culture that gives you the opportunity to innovate, to make decisions, to achieve your own potential and to chart your own career.
Pharmathen is an equal opportunity employer. We welcome applications regardless of gender, race, age, religion, sexual orientation, and national origin.
Founded in 1969, Pharmathen has grown to become one of the largest, vertically integrated developers of complex drug delivery technologies.
Pharmathen is committed to its vision to improve people’s lives through innovation and access to affordable medicines.
The company has one of the most extensive and advanced pipelines in the industry, with a focus on long acting injectables (LAI), sustained release and ophthalmic formulations. Pharmathen’s highly diversified portfolio consists of over 100 commercialized products, which are produced in its US FDA and EU-approved manufacturing facilities in Greece, serving 250 customers and accessed by patients in more than 90 countries worldwide.
Pharmathen is constantly strengthening its portfolio with innovative technologies and Long-Acting Therapeutic Technologies (LATTs) and has developed three fully certified technological platforms to achieve this. As a result, Pharmathen can provide a wide range of therapies which aim to improve treatment compliance for patients and support product Life Cycle Management (LCM) opportunities for customers.
Pharmathen maintains a strong presence in all major markets and collaborates with the most significant organizations in the global pharmaceutical market, supported by a broad partner network in more than 90 countries worldwide. The company ranks among the top 50 pharmaceutical research companies in Europe and is one of the largest private sector investors in research and development in Greece.
Pharmathen proudly employs more than 1,600 people from over 28 different nationalities, with 54% of its total workforce and 66% of its Research Operations Team being female. The company's enduring success is attributed to a passion for creativity, strong ethics, and the dedication of its people, who share a commitment to the company's vision of making a difference in people’s lives.
